|
|
Volumn 45, Issue 7, 2007, Pages 55-56
|
|
Understanding monoclonal antibodies
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABCIXIMAB;
ADALIMUMAB;
ALEMTUZUMAB;
BASILIXIMAB;
BEVACIZUMAB;
CETUXIMAB;
DACLIZUMAB;
EFALIZUMAB;
EPIDERMAL GROWTH FACTOR RECEPTOR 2;
IBRITUMOMAB TIUXETAN;
IMMUNOGLOBULIN A ANTIBODY;
IMMUNOGLOBULIN D ANTIBODY;
IMMUNOGLOBULIN E ANTIBODY;
IMMUNOGLOBULIN G ANTIBODY;
IMMUNOGLOBULIN M ANTIBODY;
INFLIXIMAB;
MONOCLONAL ANTIBODY;
NATALIZUMAB;
OMALIZUMAB;
PALIVIZUMAB;
RANIBIZUMAB;
RITUXIMAB;
SULESOMAB;
SULESOMAB TC 99M;
TRASTUZUMAB;
TUMOR NECROSIS FACTOR ALPHA;
ANTIBODY PRODUCTION;
ANTINEOPLASTIC ACTIVITY;
ASTHMA;
B LYMPHOCYTE;
BONE INFECTION;
BREAST CANCER;
CANCER INHIBITION;
COLORECTAL CANCER;
DIAGNOSTIC VALUE;
DRUG HALF LIFE;
DRUG MANUFACTURE;
DRUG SYNTHESIS;
DRUG TARGETING;
DRUG USE;
GENETIC ENGINEERING;
HUMAN;
NOMENCLATURE;
NONHUMAN;
RETINA MACULA AGE RELATED DEGENERATION;
RETINA NEOVASCULARIZATION;
REVIEW;
RHEUMATOID ARTHRITIS;
UNITED KINGDOM;
ANTIBODIES, MONOCLONAL;
HUMANS;
RECOMBINANT FUSION PROTEINS;
TECHNOLOGY, MEDICAL;
|
|
EID: 34447137028
PISSN: 00126543
EISSN: None
Source Type: Journal
DOI: 10.1136/dtb.2007.45755 Document Type: Review |
|
Times cited : (7)
|
|
References (10)
|
